Physician profile
Seth Benkel
NPI 1932143518
$11,157.49
in general payments reported to CMS, 2019-2025
56 companies · $945 in 2025
The $945 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,923 · 2020: $1,184 · 2021: $2,270 · 2022: $1,601 · 2023: $1,332 · 2024: $901 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,989 · Long Term Medical Supply Or Device Loan: $167 · Education: $22.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,989.02 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $22.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,510.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $679.82 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Astrazeneca Pharmaceuticals LP | $661.94 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $556.32 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Merck Sharp & Dohme LLC | $553.81 | 2019-2025 | Keytruda, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $463.38 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| Amgen INC. | $450.88 | 2019-2023 | Lumakras, Kyprolis |
| Tosoh Bioscience, INC. | $427.00 | 2019 | |
| Pfizer INC. | $417.80 | 2019-2024 | |
| Genentech USA, INC. | $338.96 | 2019-2025 | Venclexta, Polivy |
| Celgene Corporation | $306.56 | 2019-2024 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $306.41 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Genzyme Corporation | $262.84 | 2019-2022 | |
| Abbvie INC. | $253.18 | 2019-2025 | Venclexta |
| Seagen INC. | $229.13 | 2019-2023 | Adcetris |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Benkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.